Lupin introduces Norco generic
MUMBAI and BALTIMORE — Lupin has launched its generic of Norco (hydrocodone bitartrate and acetaminophen) tablets. The drug is indicated to relieve moderate to moderately severe pain.
Lupin’s generic will be available in dosage strengths of 5 mg/325 mg, 7.5 mg/325 mg and 10 mg/325 mg. The drug had annual U.S. sales of $710 million for the 12 months ended June 2017, according to QuintilesIMS data.
Upsher-Smith launches generic Aromasin
MAPLE GROVE, Minn. — Upsher-Smith Laboratories has introduced its generic of Aromasin (exemestane) tablets. The drug is an aromatase inhibitor indicated as an adjuvant treatment in postmenopausal women with breast cancer than has been treated with tamoxifen.
"We are pleased to offer physicians and patients a cost-effective alternative to Aromasin.” Upsher-Smith president and CEO Rusty Field said. "The addition of exemestane tablets supports our company's ongoing commitment to expanding our product portfolio and making quality, reasonably priced generics available to the most patients possible.”
The drug had U.S. sales of approximately $84 million for the 12 months ended August 31, according to QuintilesIMS data. It is available in 25-mg dosage strength.
Lupin acquires Symbiomix Therapeutics
MUMBAI, India — Lupin’s U.S. subsidiary’s latest acquisition is set to strengthen its pipeline for gynecologic drugs. The company has acquired Symbiomix Therapeutics for $150 million, which includes an upfront payment of $50 million and closed today.
With the acquisition, Lupin brings into its portfolio the Symbiomix’s Solosec franchise, expanding its women’s health specialty business, currently anchored by Lupin’s Methergine tablets. Solosec oral granules — a single-dose treatment for bacterial vaginosis — was approved by the Food and Drug Administration in mid-September and is set to be launched mid-2018. Having been designated by the FDA as a Qualified Infectious Disease Product, Solosec is eligible for 10 years of U.S. exclusivity, the company said.
“We are delighted to complete the acquisition of Symbiomix and its Solosec brand, which immediately expands Lupin’s U.S. women’s health specialty business into the highly-complementary gynecological infection sector,” Lupin CEO Vinita Gupta said. “This transaction is an important milestone in the evolution of our Specialty business and gives Lupin a new therapeutic to bring to obstetricians and gynecologists to treat a serious health condition they see frequently in their practices.”